What is the clinical evidence from this study?

Study design: Observational. Population: Coronary atherosclerosis with metabolic syndrome or type 2 diabetes. Intervention: Pioglitazone vs. Control subjects with minimal/no CAD and no MS/T2D. Primary outcome: Changes in gene expression in epicardial and subcutaneous adipose tissue.

February 3, 2011Open Access

Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes

Key Result

Pioglitazone therapy in type 2 diabetes with coronary atherosclerosis was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in epicardial adipose tissue.

Study Design

Type

Observational

Structured PICO

Does pioglitazone therapy alter inflammatory gene expression in epicardial adipose tissue in patients with coronary atherosclerosis and type 2 diabetes?

Population

Patients with coronary atherosclerosis (CAD) and metabolic syndrome (MS) or type 2 diabetes undergoing surgery, and control subjects with minimal or no CAD and no MS or type 2 diabetes

Intervention

Pioglitazone therapy

Comparator

Control subjects with minimal or no CAD and no MS or type 2 diabetes, and patients not receiving pioglitazone

Outcome

Gene expression of IL-1Ra, IL-10, IL-1β, and PPARγ in epicardial adipose tissue (EAT) and thoracic subcutaneous adipose tissue (SAT) quantified by RT-PCRsurrogate

Pioglitazone therapy is associated with a reduction in inflammatory gene expression in the epicardial fat of patients with CAD and type 2 diabetes.

Abstract

OBJECTIVE To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator–activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS In MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.

Bookmark

View Full Paper

Cite This Study

Sacks et al. (Thu,) conducted a observational in Coronary atherosclerosis with metabolic syndrome or type 2 diabetes. Pioglitazone vs. Control subjects with minimal/no CAD and no MS/T2D was evaluated on Changes in gene expression in epicardial and subcutaneous adipose tissue. Pioglitazone therapy in type 2 diabetes with coronary atherosclerosis was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in epicardial adipose tissue.

synapsesocial.com/papers/6a0f03cdc12540356222db38 https://doi.org/https://doi.org/10.2337/dc10-2083

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper